Article

Navigating The Complexities Of An IND Submission In The Emerging Chinese Market

iStock-1256323051-scientist-research-lab-development-samples-microscope

While China’s pharmaceutical market is growing at a steady pace, the drug registration timeline and process has been notoriously complex and lengthy, leading to a severe backlog of investigational new drug (IND) application submissions and an average delay as long as 14 months to register a clinical trial for an innovative drug.1 These challenges, combined with a focus on driving new drug innovation in China, led to efforts in 2015 to amend and reform the review and approval system for drugs and medical devices in China as well as improve drug quality.2

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: